INDIVIDUAL DIFFERENCES IN THE PHARMACOKINETICS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS: ROLE OF GENETIC AND ENVIRONMENTAL FACTORS AND CLINICAL IMPORTANCE*
- 1 July 1971
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 179 (1), 739-751
- https://doi.org/10.1111/j.1749-6632.1971.tb46949.x
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- The role of plasma protein binding in the inhibitory effect of nortriptyline on the neuronal uptake of norepinephrineClinical Pharmacology & Therapeutics, 1970
- The pH‐dependent excretion of mono methylated tricyclic antidepressants; In dog and manClinical Pharmacology & Therapeutics, 1969
- Plasma protein binding of tricyclic anti-depressants in manBiochemical Pharmacology, 1969
- A comparative study of the metabolism of desmethylimipramine, nortriptyline, and oxyphenylbutazone in manClinical Pharmacology & Therapeutics, 1969
- Genetic control of dicumarol levels in manJCI Insight, 1968
- Genetic Control of Drug Levels in Man: AntipyrineScience, 1968
- GENETIC VARIATIONS IN THE ACETYLATION OF ISONIAZID AND OTHER DRUGSAnnals of the New York Academy of Sciences, 1968
- Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compoundsLife Sciences, 1967
- Biogenic Amines and EmotionScience, 1967
- Blood Levels of Drug at the Equilibrium State after Multiple DosingNature, 1965